Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Phase II clinical trial on mitoxantrone].

H R Gao1

  • 1Cancer Hospital, Shanghoi University of Medical Sciences.

Zhonghua Zhong Liu Za Zhi [Chinese Journal of Oncology]
|May 1, 1989
PubMed
Summary

This study evaluated mitoxantrone for advanced cancers, showing varied response rates across cancer types. Mitoxantrone demonstrated efficacy in certain leukemias and lymphomas, with manageable side effects like leukopenia.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Fluoxetine hydrochloride ameliorates symptoms of hepatic myelopathy: a case report].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology·2024
Same author

[Seroepidemiological investigation of hepatitis C virus in Zhejiang Province: a hospital-based study].

Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology·2019
Same author

Dopamine involved in the nociceptive modulation in the parafascicular nucleus of morphine-dependent rat.

Neurochemical research·2011
Same author

L-364,718 potentiates electroacupuncture analgesia through cck-a receptor of pain-related neurons in the nucleus parafascicularis.

Neurochemical research·2010
Same author

[Identification of Bungarus Parvus and its confused snakes].

Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica·1994
Same author

[Comparison of two multi-drug chemotherapy regimens based on mitoxantrone and epirubicin in 44 patients with non-Hodgkin's lymphoma].

Zhonghua zhong liu za zhi [Chinese journal of oncology]·1991

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Medicine

Background:

  • Mitoxantrone is an anthracenedione antineoplastic agent.
  • Advanced cancers present significant treatment challenges.

Purpose of the Study:

  • To evaluate the efficacy and safety of mitoxantrone in patients with various advanced cancers.
  • To determine objective response rates for different cancer types treated with mitoxantrone.

Main Methods:

  • A prospective study involving 154 patients with pathologically confirmed advanced cancers.
  • Mitoxantrone administered intravenously at a dose of 14 mg/M2 every 3-4 weeks.
  • Patient demographics included age range (16-76 years) and gender distribution (96 males, 58 females).

Main Results:

  • Objective response rates varied by cancer type: breast cancer (21%), non-Hodgkin's lymphoma (36%), acute lymphocytic leukemia (56%), acute nonlymphocytic leukemia (14%), gastric cancer (31%), and primary hepatic cancer (5%).
  • The most common side effects observed were leukopenia and gastro-intestinal disturbances.
  • No significant cardiac toxicity was noted during the study period.

Conclusions:

  • Mitoxantrone shows promising efficacy in specific hematological malignancies like acute lymphocytic leukemia and non-Hodgkin's lymphoma.
  • The drug is generally well-tolerated, with manageable side effects, and lacks significant cardiotoxicity.
  • Further investigation into mitoxantrone's role in other advanced solid tumors may be warranted based on observed response rates.

Related Experiment Videos